13th week of 2014 patent applcation highlights part 42 |
Patent application number | Title | Published |
20140086907 | MULTIMODAL TRAIL MOLECULES AND USES IN CELLULAR THERAPIES - Described herein are novel compositions comprising multimodal TRAIL agents and cells engineered to express such multimodal TRAIL agents, including cells encapsulated in a scaffold or matrix, for use in the treatment of disorders such as cancer. | 2014-03-27 |
20140086908 | ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF PROSTATE CANCER - The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration-resistant prostate cancer (CRPC), optionally accompanied by lymph node and bone tissue metastases (mCRPC). In particular, the invention relates to the therapy of said patients by means of the anti-angiogenic antibody DI17E6 and structural mutants thereof. | 2014-03-27 |
20140086909 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS - The invention features methods of treating a proliferative disorder characterized by elevated Pin1 marker levels and/or reduced Pin1 Ser71 phosphorylation in a subject by administering a retinoic acid compound. Additionally, the invention features methods of treating proliferative disorders (e.g., proliferative disorders characterized by elevated Pin1 marker levels) by administering a retinoic acid compound in combination with another anti-proliferative compound. Finally, the invention also features methods including high-throughput screens for discovering and validating Pin1 inhibitors. | 2014-03-27 |
20140086910 | METHODS OF TREATING OR PREVENTING ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES - The present invention provides indane acetic acid and their derivatives and methods for the treating and/or preventing of Alzheimer's diseases. | 2014-03-27 |
20140086911 | Methods and Products for Predicting CMTC Class and Prognosis in Breast Cancer Patients - Provided herein are products, uses and method classifying a subject afflicted with breast cancer according to a ClinicoMolecular Triad Classification (CMTC)-1, CMTC-2 or CMTC-3 class. The method involves:
| 2014-03-27 |
20140086912 | HUMANIZED ANTI-INTERLEUKIN 3 RECEPTOR ALPHA CHAIN ANTIBODIES - The present disclosure provides antibodies that bind to interleukin-3 receptor alpha chain and uses thereof. | 2014-03-27 |
20140086913 | ANTI-DDR1 ANTIBODIES - Provided are antibodies, including functional antibody fragments, that specifically bind to discoidin domain receptors (DDRs), and in particular to DDR1 proteins, as well as uses and method of using such antibodies, including in the detection, diagnosis and treatment of diseases and conditions associated with DDR1. | 2014-03-27 |
20140086914 | TREATMENT METHODS USING c-MET ANTIBODIES - The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to c-Met, preferably human c-Met, and that function to inhibit c-Met. The invention also relates to human anti-c-Met antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-c-Met antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-c-Met antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-c-Met antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention. | 2014-03-27 |
20140086915 | AGENTS AND METHODS FOR MODULATING MACROPHAGE INHIBITORY CYTOKINE (MIC-1) ACTIVITY - The invention relates to a method and novel types of agents for modulating appetite and/or body weight in a subject. Moreover, the invention relates to a method of screening for agents which interact and modulate the activity of the receptor complex for macrophage inhibitory cytokine-1 (MIC-1). | 2014-03-27 |
20140086916 | METHOD FOR PREPARING Fc CONTAINING POLYPEPTIDES HAVING IMPROVED PROPERTIES - The present invention is directed to methods and compositions for the production of Fc-containing polypeptides comprising mutations at positions 243, 264, 267 and 328 of the Fc region. | 2014-03-27 |
20140086917 | COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER - An article-of-manufacture is provided. The article-of-manufacture comprises a packaging material identified for treating cancer, packaging:
| 2014-03-27 |
20140086918 | Methods for Inhibiting Prostate Cancer - The invention provides methods for reducing growth and/or metastasis of androgen-independent (castration resistant) prostate cancer in a tissue in an animal. In one embodiment the method comprises administering to the animal a therapeutically effective amount of a compound that reduces the number of B cells, and/or the function of B cells, in the tissue. In yet another embodiment, the invention provides methods for reducing androgen-induced growth of prostate epithelial cells in prostate tissue in an animal. In one embodiment, the method comprises administering to the animal a therapeutically effective amount of a compound that reduces the number of B cells, and/or the function of B cells, in the tissue. | 2014-03-27 |
20140086919 | METHODS AND COMPOSITONS FOR REGULATING IRON HOMEOSTASIS BY MODULATION OF BMP-6 - Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of hemochromatosis and anemia of inflammation. | 2014-03-27 |
20140086920 | Antagonist Antibodies against GDF-8 and Uses in Treatment of ALS and Other GDF-8 Associated Disorders - The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention. | 2014-03-27 |
20140086921 | Methods of Treating a Tauopathy - The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods. | 2014-03-27 |
20140086922 | ANTI-IL-12/IL-23 ANTIBODIES - Provided herein is an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80), and the antibody inhibits the binding of human IL-12 to human IL-12Rβ2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12Rβ1. | 2014-03-27 |
20140086923 | Antibodies Directed Against ICOS and Uses Thereof - The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFNγ production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg. | 2014-03-27 |
20140086924 | COMPOUNDS THAT INHIBIT HSP90 PROTEIN-PROTEIN INTERACTIONS WITH IAP PROTEINS - Disclosed herein are compounds that inhibit Hsp90 interactions with IAP proteins, such as Survivin, XIAP, cIAP1, or cIAP2, and methods for identifying and using such compounds. | 2014-03-27 |
20140086925 | FGFR1 ANTIBODIES AND TREATMENT OF CANCER - The use of an FGFR1 antibody in the treatment of cancer is disclosed, wherein the FGFR1 antibody binds FGFR1 at an epitope that is positioned in the FGFR1 primary amino acid sequence no more than 50 contiguous amino acids away from the C- or N-terminal of the FGFR1 heparin binding domain. | 2014-03-27 |
20140086926 | METHOD OF COMBINATION THERAPY FOR PREVENTION OR TREATMENT OF C-MET OR ANGIOGENESIS FACTOR INDUCED DISEASES - Provided is a method of combination therapy for prevention or treatment of c-Met-induced or angiogenesis factor-induced diseases including co-administering an angiogenesis inhibitor and an anti-c-Met antibody or an antigen-binding fragment thereof to a patient. | 2014-03-27 |
20140086927 | NOVEL EPITOPE AND MECHANISM OF ANTIGEN-ANTIBODY INTERACTION IN AN INFLUENZA VIRUS - Antibodies (Abs) play roles in protection against influenza. Neutralizing Abs either inhibit the binding of hemagglutinin (HA) to cellular receptors or prevent the conformational change of HA induced by low pH. The former Ab binds to the regions near the sialic acid-binding pocket on the globular head formed by HA1 and generally shows narrow strain specificity. The latter Ab binds to the stem region formed mainly by HA2 and shows broad strain specificity. We isolated a broadly neutralizing Ab against H3N2 viruses. X-ray analysis of the HA/Ab complex indicated that the Ab binds to the valley formed by two neighboring HA monomers at the side of the globular head. The Ab shows neutralizing activity by preventing the conformational change of HA induced at low pH. | 2014-03-27 |
20140086928 | Antigenic GM-CSF Peptides and Antibodies to GM-CSF - Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease. | 2014-03-27 |
20140086929 | FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS - A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability. | 2014-03-27 |
20140086930 | FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS - A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability. | 2014-03-27 |
20140086931 | FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS - A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability. | 2014-03-27 |
20140086932 | METHOD FOR ENHANCING SPECIFIC IMMUNOTHERAPIES IN CANCER TREATMENT - Methods and compositions of the invention relate to the enhancement of specific immunotherapies in cancer treatment. In particular, aspects of the invention relate to novel approaches to boost immune function using a complex carbohydrate pharmaceutical compound alone or in combination with other targeted immunotherapy to increase the efficacy of immunotherapy of cancer. | 2014-03-27 |
20140086933 | Treatment of Diabetes - Glycated hemoglobin (HbA1c) levels and other characteristics of diabetes are reduced by administering to a human subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α. | 2014-03-27 |
20140086934 | METHOD FOR TREATING INTRAOCULAR NEOVASCULAR DISEASES - A method is provided for administering to a mammal suffering from, or at risk for, an intraocular neovascular disorder with regular dosing of a therapeutically effective amount of VEGF antagonist, followed by less frequent dosing of a therapeutically effective amount of VEGF antagonist. | 2014-03-27 |
20140086935 | Human TIMP-1 Antibodies - Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis. | 2014-03-27 |
20140086936 | MATRIPTASE INHIBITORS AND USES THEREOF AGAINST ORTHOMYXOVIRIDAE INFECTIONS - The present invention provides matriptase inhibitors and compositions for treating and preventing orthomyxovirus infections such as flu infections. The present invention also provides novel compounds, compositions, methods of use, uses and kits thereof for inhibiting matriptase. Such compounds are useful for treating and preventing orthomyxovirus infections, such as flu infections, and for inhibiting tumor growth, progression and/or metastasis. | 2014-03-27 |
20140086937 | IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO - Disclosed herein are compositions and methods useful for controlling β-amyloid levels. In particular, the instant invention relates to an antibody that catalyzes hydrolysis of β-amyloid at a predetermined amide linkage are provided. The present invention also provides a vectorized antibody that is capable of crossing the blood brain barrier and is also capable of catalyzing the hydrolysis of β-amyloid at a predetermined amide linkage. Also provided are methods for modulating β-amyloid levels in vivo using antibodies that bind to β-amyloid. These compositions and methods have therapeutic applications, including the treatment of Alzheimer's disease. | 2014-03-27 |
20140086938 | METHODS OF INHIBITING TUMOR GROWTH USING TTK ANTAGONISTS - The present invention relates to methods for treating TTK positive breast cancers or soft-tissue sarcomas in a mammalian subject by administering a therapeutically effective amount of a TTK antagonist. The invention also provides compositions comprising a TTK antagonist and a HER-2 antagonist, as well as methods of diagnosing a basal-like breast cancer and methods of determining the prognosis of a subject having a cancer by assessing expression of TTK in a tumor sample from a subject. | 2014-03-27 |
20140086939 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING CANCER - The invention provides methods for detecting the presence of cancer initiating cells in a tissue, methods for identifying test agent for reducing cancer, and methods for reducing cancer in a subject. The invention's methods are applicable to any cancer, and in particular to liver cancer. The invention also provides the isolation and characterization of pre-malignant hepatocellular carcinoma initiating cells (HICs). The invention further provides methods for isolating hepatocellular carcinoma initiating cells (HICs), methods for using the isolated cells for screening anti-cancer drugs, methods for using HIC markers for the early diagnosis of hepatocellular carcinoma, and methods for the prevention and/or delay of hepatocellular carcinoma by using agents that selectively deplete the number and/or malignant properties of HICs. | 2014-03-27 |
20140086940 | HERCEPTIN.RTM. ADJUVANT THERAPY - The present application describes adjuvant therapy of nonmetastatic breast cancer using HERCEPTIN®. | 2014-03-27 |
20140086941 | SUBSTITUTED 2-BENZYLIDENE-2H-BENZO[b][1,4]THIAZIN-3(4H)-ONES, DERIVATIVES THEREOF, AND THERAPEUTIC USES THEREOF - The present invention relates to compounds according to Formula I: | 2014-03-27 |
20140086942 | Variant Target Binding Agents and Uses Thereof - The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells. | 2014-03-27 |
20140086943 | NOVEL AND POWERFUL MHC-CLASS II PEPTIDES DERIVED FROM SURVIVIN - The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 2014-03-27 |
20140086944 | DNA VACCINE CONTAINING SPECIFIC EPITOPE OF APOLIPOPROTEIN (a) - The present invention provides an agent for the treatment or prophylaxis of arteriosclerosis comprising an expression vector encoding a chimeric Hepatitis B virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of apolipoprotein (a), wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide. | 2014-03-27 |
20140086945 | ALBUMIN-AMYLOID PEPTIDE CONJUGATES AND USES THEREOF - The invention provides conjugates comprising albumin and a peptide derived from the C-terminal region of amyloid beta peptide, as well as uses thereof for the treatment of diseases characterized by the deposition of amyloid proteins and, in particular, for the treatment of Alzheimer's disease. | 2014-03-27 |
20140086946 | Uses of an Immunomodulatory Protein (GMI) from Ganoderma Microsporum - The invention provides a method for inhibiting EGF receptor activity comprising contacting an EGF receptor with an immunomodulatory protein (GMI) from | 2014-03-27 |
20140086947 | VACCINES FOR HSV-2 - Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects. | 2014-03-27 |
20140086948 | TUBERCULOSIS RV2386C PROTEIN, COMPOSITIONS AND USES THEREOF - The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; of (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis. | 2014-03-27 |
20140086949 | Ghrelin Mimetic Polypeptide Hapten Immunoconjugates Having Improved Solubility and Immunogenicity and Methods of Use Thereof - Immunoconjugates for impeding weight gain and treating obesity in a subject are disclosed. The immunoconjugates comprise a ghrelin mimetic polypeptide hapten, a spacer moiety comprising one of more polyethylene glycol (PEG) units, and a protein carrier moiety. Immunoconjugates optionally include a conjugation moiety for conjugating the polypeptide hapten with a linker moiety or the protein carrier moiety and a linker moiety for conjugating the conjugation moiety with the protein carrier moiety. | 2014-03-27 |
20140086950 | RECOMBINANT LACTOCOCCUS LACTIS EXPRESSING ESCHERICHIA COLI COLONIZATION FACTOR ANTIGEN I (CFA/I) FIMBRIAE AND THEIR METHODS OF USE - The present disclosure relates generally to therapeutic compositions comprising recombinant bacteria. Further, the disclosure elaborates upon methods of utilizing the taught therapeutic compositions to treat autoimmune and inflammatory disease. The present teachings also relate to the disclosed recombinant bacteria and methods of producing the recombinant bacteria utilized in the compositions and methods. Further taught herein are dietary supplements and food additive compositions comprising the taught recombinant bacteria. | 2014-03-27 |
20140086951 | Pharmaceutical Composition and Methods for Modulating Immune System, Preventing, Pretreating and/or Treating Cancers - This invention provides a pharmaceutical composition for modulating immune system comprising at least one polysaccharide extracted from Radix Astragali, Radix Codonopsis, | 2014-03-27 |
20140086952 | Vaccine Adjuvants from Self-Assembling Peptides - Pharmaceutical or veterinary compositions, vaccine systems, methods, and kits for treating or protecting a subject from a condition using peptide-based adjuvants are provided. The peptide adjuvants comprise a peptide having a hydrophobic region, a turning region, and a hydrophilic region. The turning region comprises amino acid residues GSII (SEQ ID NO: 10). The peptide adjuvants can be used to immunopotentiate active agents by improving the immune response to the active agent. | 2014-03-27 |
20140086953 | ATTENUATED CHIKUNGUNYA VIRUS - Novel attenuating deletions of Chikungunya virus E2 polypeptides are provided as are attenuated viruses comprising the deletions. Also provided are immunogenic compositions comprising the attenuated viruses and methods of producing such viruses in cells (such as insect cells). Viruses of the embodiments can be used for immunization of animals to provide protection from the pathogenic effects of Chikungunya virus infection. | 2014-03-27 |
20140086954 | USE OF BLOOD OR TISSUE BACTERIOME FOR PREDICTION, DIAGNOSIS AND PREVENTION OF METABOLIC DISEASES AND THEIR CARDIOVASCULAR COMPLICATIONS - The present invention relates to the use of the bacterial flora for vaccine development, identification of therapeutic targets and prediction and/or diagnosis of metabolic diseases, such as diabetes, overweight and obesity, and their cardiovascular complications. In particular, the present invention provides immunogenic or vaccinal composition for preventing metabolic diseases and cardiovascular complications using attenuated or inactivated bacterial flora, or antigens derived thereof. The present invention also provides methods for identifying prognostic markers for metabolic diseases onset and cardiovascular complications and methods for in vitro prognosis of metabolic diseases and cardiovascular complications using bacterial flora. | 2014-03-27 |
20140086955 | Attenuated Live Vaccines for Aquatic Animals - Safe and effective live vaccines against bacteria infecting aquatic animals were created through the induction of novobiocin-resistance in liquid culture and novobiocin- and rifampicin-resistance in liquid culture. | 2014-03-27 |
20140086956 | ADJUVANT FOR THE PREPARATION OF VACCINE COMPOSITIONS INTENDED FOR THE PREVENTION OF COCCIDIOSIS - A vaccine adjuvant which, based on the 100% mass thereof, includes between 10% and 95% of a mineral oil containing: between 0.05 mass-% and 10 mass-% hydrocarbon chains having less than 16 carbon atoms, and between 0.05 mass-% and 5 mass-% hydrocarbon chains having more than 28 carbon atoms. In addition, the adjuvant has a P/N ratio, corresponding to the ratio of the mass quantity of the paraffinic hydrocarbon chains to the mass quantity of the naphthenic hydrocarbon chains, of between 2.5 and 3, the adjuvant being intended for the production of a vaccine composition to prevent coccidiosis. | 2014-03-27 |
20140086957 | MEANS AND METHODS FOR ACTIVE CELLULAR IMMUNOTHERAPY OF CANCER BY USING TUMOR CELLS KILLED BY HIGH HYDROSTATIC PRESSURE AND DENDRITIC CELLS - Disclosed are pharmaceutical compositions for inducing an immune response against tumor cells comprising tumor cells which are made apoptotic by treatment with high hydrostatic pressure and dendritic cells, and methods for producing such compositions. | 2014-03-27 |
20140086958 | Biomarker for Selecting Patients and Related Methods - The present invention concerns methods for inducing an immune response to an antigen in a patient for treating human disease by administering an immunogenic composition wherein said patient is selected in a patient population of interest. The present invention further concerns methods for determining whether a subject is or is not susceptible to developing a prophylactic or therapeutic immune response after such treatment. | 2014-03-27 |
20140086959 | METHOD FOR PRODUCING MILK HAVING AN IMMUNOREGULATORY ACTION - A method for screening for a foodstuff providing production of milk having an immunoregulatory action, a foodstuff having an immunoregulatory action, and a method for producing it are provided. A diet or substance that increases or decreases an amount of microRNA present in milk of a mammal is identified by using correlation of microRNA profiles in the milk and a diet ingested by the mammal or a substance contained in the diet as an index to screen for a diet or a substance providing production of breast milk having an immunoregulatory action. | 2014-03-27 |
20140086960 | IMMUNOMODULATORY COMPOUNDS AND TREATMENT OF DISEASES RELATED TO AN OVERPRODUCTION OF INFLAMMATORY CYTOKINES - Method of using immunomodulatory compounds for treating diseases related to an overproduction of inflammatory cytokines, including diseases selected from asthma, atopic dermatitis, allergic rhinitis, prostatitis, inflammatory bowel disease, diabetes, and rheumatoid arthritis, the compounds being of general formula (I): | 2014-03-27 |
20140086961 | USE OF CYCLODEXTRINS IN DIETS, WATER OR VACCINE ADJUVANTS TO BOOST THE IMMUNE SYSTEM OF FISH - The present disclosure describes compositions containing cyclodextrin and methods of using cyclodextrins to stimulate or enhance the immune system and response in fish. Methods of enhancing the efficacy of a fish vaccine by administering cyclodextrin to the fish are also described. | 2014-03-27 |
20140086962 | PRODUCTS OF MANUFACTURE HAVING TANTALUM COATED NANOSTRUCTURES, AND METHODS OF MAKING AND USING THEM - In alternative embodiments, the invention provides products (articles) of manufacture comprising nanostructures such as nanotubes having a surface comprising tantalum. In alternative embodiments, products of manufacture of the invention include nanostructures, e.g., nanotubes, nanowire, nanopore, and the like comprising a surface layer of tantalum. In alternative embodiments, products or articles of manufacture of the invention are bioimplants, and the tantalum-surface-coated nanostructures of the invention provide increased bioactivity and bone forming ability. In alternative embodiments, products or articles of manufacture of the invention, e.g., bioimplants, comprising the tantalum-surface-coated nanostructures of the invention are used for in vitro, ex vivo and in vivo testing, implants, biomedical devices and therapeutics. | 2014-03-27 |
20140086963 | METHODS OF WOUND CARE AND TREATMENT - Particular embodiments disclosed herein relate to gas-enriched fluids, methods of making the same, systems for making the same and/or methods of treatment utilizing the gas-enriched fluids for wound care related conditions and/or diseases. In certain embodiments, the gas-enriched fluid is oxygen-enriched water. Certain embodiments relate to cosmetic and/or therapeutic fluids and/or methods of treatment utilizing the fluids in order to treat a cosmetic and/or therapeutic symptom of wound care and/or increase proper wound healing. | 2014-03-27 |
20140086964 | Slurry Powder Cosmetic Compositions and Methods - Slurry powder cosmetic composition comprising particulates coated with a binder composition, a silicone gel composition, and the evaporation residue of an aqueous based composition and a method for making the composition. | 2014-03-27 |
20140086965 | Spray Drying Microcapsules - Spray drying microcapsules with particulates, the microcapsules that result from such spray drying, and compositions and methods of making said compositions including the spray-dried microcapsules. | 2014-03-27 |
20140086966 | ULTRAVIOLET-SHIELDING AGENT, METHOD FOR PRODUCING THE SAME, ULTRAVIOLET-SHIELDING AGENT-CONTAINING DISPERSION LIQUID, AND COSMETIC PREPARATION - The invention provides an ultraviolet-shielding agent including resin particles formed by coating a core portion with a coating layer, wherein the core portion is made of any one resin of an organic ultraviolet absorbent-containing resin and an inorganic particle-containing resin, and the coating layer is made of the other resin or both resins, a method for producing the same, an ultraviolet-shielding agent-containing dispersion liquid, and a cosmetic preparation. | 2014-03-27 |
20140086967 | ADHESIVE COMPOSITION FOR SOFT TISSUES, ADHESIVE COMPOSITION FOR WOUND DRESSING OR WOUND DRESSING COMPOSITION - The present invention provides an adhesive composition for soft tissues, an adhesive composition for wound dressing or a wound dressing composition, not only having low toxicity, low harmfulness and high adhesive strength but also being excellent in workability during application and being capable of forming films of excellent properties. The compound of the present invention is comprised a monomer (A), polymer particles (B) having a specific weight-average molecular weight and a specific volume mean particle diameter, and a polymerization initiator composition (C) containing an organoboron compound is produced. | 2014-03-27 |
20140086968 | Chemical Composition with Hydrogen Peroxide and a Nanoemulsion of Long-Chained Alcohols - The present invention provides a chemical composition comprised of hydrogen peroxide and a nanoemulsion of long-chained alcohols which in combination these constituents act synergistically boost the kill-time rate of hydrogen peroxide. The peroxide based nanoemulsion formulation for application to skin includes a cosmetically approved peroxide containing compound present in a range to give from about 0.1 to about 4 wt./wt. % released hydrogen peroxide, an organic acid present in a concentration from about 0.01 to about 5 wt./wt. % for adjusting a pH of the formulation in a range from about pH 1 to about pH 4, a long-chained (C9 to C22) aryl and/or alkl alcohol, present in a concentration from about 0.1 to about 20 wt./wt. %, and an emollient present in a concentration from about 0.1 to about 40 wt./wt. %, and an emulsifier present in a concentration from about 0.1 to about 20 wt./wt. % to render the formulation a nanoemulsion. | 2014-03-27 |
20140086969 | UV-RESISTANT GELATIN/SILICA VIRAL PARTICLES, PREPARATION METHOD AND USES THEREOF - Disclosed herein are UV-resistant gelatin/silica coated viral particles, methods for producing the same, and methods for controlling agricultural insect pests using the UV-resistant gelatin/silica coated viral particles. | 2014-03-27 |
20140086970 | SILVER CHLORIDE COMPOSITIONS FOR DEODORIZATION AND DISINFECTION - An antimicrobial system including inert carrier particles coated with a silver salt in combination with a primary disinfectant is disclosed. Some aspects relate to a disposable wipe for use in cleaning and disinfecting, the disposable wipe including a antimicrobial system. Other aspects relate to a sprayable disinfectant including a liquid carrier. Inert carrier particles, coated with a silver salt, are dispersed in the liquid carrier with a primary disinfectant. Optional additives including surfactants, dispersants, and stabilizers, may also be added. | 2014-03-27 |
20140086971 | DRUG-ELUTING ROTATIONAL SPUN COATINGS AND METHODS OF USE - Drug-eluting rotational spun coatings that include one or more therapeutic agents may be used to coat a medical device. The medical devices include, for example, balloon catheters, vascular grafts and stents, which are coated with drug-eluting rotational spun materials that may be used to deliver a therapeutic agent to a target tissue or body lumen. | 2014-03-27 |
20140086972 | MICROFABRICATED NANOPORE DEVICE FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT - A drug delivery device that includes a capsule for implantation into the body; the capsule further includes a reservoir for containing a substance such as a therapeutic agent, at least one port for allowing the substance to diffuse from or otherwise exit the reservoir, and a nanopore membrane in communication with the capsule at or near the exit port for controlling the rate of diffusion of the substance from the exit port. The device also includes an optional screen for providing structural stability to the nanopore membrane and for keeping the pores of the nanopore membrane clear. One embodiment of the drug delivery device includes an osmotic engine internal to the device for creating fluid flow through the device. | 2014-03-27 |
20140086973 | PHARMACEUTICAL PREPARATION - The present invention provides a pharmaceutical preparation comprising a layer-by-layer thin film that is produced by alternately layering a polycation and a polyanion, and a drug loaded onto the layer-by-layer thin film. As a result, a pharmaceutical preparation with a prolonged duration of drug action with a single dose is provided. | 2014-03-27 |
20140086974 | BIODEGRADABLE DRUG DELIVERY SYSTEMS FOR THE SUSTAINED RELEASE OF PROTEINS - Biodegradable drug delivery systems, such as extruded implants, for the sustained delivery of a protein to an ocular region of the eye or intraarticular region in the body are described. The drug delivery systems may be used to treat a variety of ocular and medical conditions, including macular degeneration. Methods for using and making the drug delivery systems are also described. The drug delivery systems can be in the form of extruded filaments configured for placement in an ocular region such as the vitreous body or anterior chamber of the eye. | 2014-03-27 |
20140086975 | HYDROGEL FORMULATION FOR DERMAL AND OCULAR DELIVERY - Formulations of cross-linkable polymers, capable of forming non-toxic and biocompatible hydrogels in situ, containing at least one of doxycycline or minocycline. Methods of using the hydrogels for treating the skin or ocular tissues of mammals exposed to vesicant compounds such as sulfur mustard (SM), nitrogen mustard (NM) or half mustard (2-chloroethyl ethyl sulfide (CEES)) are also disclosed. | 2014-03-27 |
20140086976 | Compositions containing protein polymers and vaccinia virus, and methods of use thereof - Provided herein are compositions containing a vaccinia virus and a protein polymer, and articles of manufacture thereof. Also provided are diagnostic and therapeutic methods using the compositions or articles of manufacture. | 2014-03-27 |
20140086977 | TIGHT JUNCTIONS MODULATORS - The present invention relates to a new therapy targeted at the restoration or improvement of tight junction function. Aberrant TJ function, is characteristic of many chronic skin diseases. The inventors demonstrated that plant polyphenols or flavonoids and Cis-urocanic acid modulates tight junction structure and function in mammalian keratinocytes and provided tight junction modulators, pharmaceutical compositions and methods for preventing or treating impaired tight junction function in stratified mammalian epithelia. | 2014-03-27 |
20140086978 | Transdermal Therapeutic System Provided With Improved Long-Term Carrying Comfort - The invention relates to transdermal therapeutic systems (TTS) comprising a backing, a reservoir layer containing at least one pharmaceutical active ingredient, and an adhesive. Said transdermal therapeutic systems are characterised in that they are able to continuously adhere to the surface of the skin over a long period of time. During said long period of time, a) there is at least one time interval during which the TTS adhering to the surface of the skin is intensively exposed to water, and b) the active ingredient is transdermally released. The invention also relates to a method for the continuous transdermal release of at least one pharmaceutical active ingredient over a long period of time. | 2014-03-27 |
20140086979 | Self-Assembling Nanoparticles for the Release of Bisphosphonates in the Treatment of Human Cancers - The present invention describe nanocomplexes also called auto-assembling nanoparticles comprising biphosphonates, lipid nanovectors and inorganic nanovectors. | 2014-03-27 |
20140086981 | PGC-1ALPHA-MODULATING PEPTIDES - Peptides of general formula (I): R | 2014-03-27 |
20140086982 | ORAL THERAPY OF NECROTIZING ENTEROCOLITIS - The present invention relates to methods of treating or reducing the risk of necrotizing enterocolitis (NEC) in an infant comprising orally administering an effective amount of a CpG-ODN. It is based, at least in part, on the results of experiments in which orally administered CpG-ODNs were observed to reduce the histopathology and markers of inflammation in a murine model for NEC. The present invention further provides for oral formulations of CpG-ODN for administration to infants. | 2014-03-27 |
20140086983 | METHODS FOR THE PREPARATION OF LIPOSOMES COMPRISING DRUGS - Provided herein are methods for preparing liposomes comprising docetaxel and uses thereof. In certain embodiments, liposomes are prepared without using heat, organic solvents, proteins, and/or inorganic salts in the process. In certain embodiments, the liposomal preparations are used in the treatment of diseases or disorders. | 2014-03-27 |
20140086984 | PHARMACEUTICAL USE OF 2-(4-MORPHOLINOANILINE)-6-CYCLOHEXYL AMINOPURINE AND PHARMACEUTICALLY ACCEPTABLE SALT OR DERIVATIVE THEREOF - The present invention provides a new use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and pharmaceutically acceptable salt or derivative thereof. The 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine can inhibit the activated hepatic stellate cells from synthesizing and expressing collagens and other extracellular matrix proteins including MMPs and TIMPs, and so it can inhibit liver fibrosis. In the liver, it can inhibit collagen synthesis and expression, and therefore reverse and treat hepatitis and liver cirrhosis effectively. Also discloses is a method for preparing drugs for treating or preventing infective hepatitis, non-infectious hepatitis, liver injury, liver cirrhosis, liver cancer and liver fibrosis, and protecting and improving the liver function, in which the compound is used alone or in combination with a target molecule or carrier comprising a vitamin A-coupled liposome. | 2014-03-27 |
20140086985 | COMPOSITION USEFUL FOR THE TREATMENT OF LIPID METABOLISM DISORDERS - The present invention relates to a composition useful for the treatment of lipid metabolism disorders, comprising one or more of the following active ingredients: (a) extract of rice fermented with | 2014-03-27 |
20140086986 | CAPSICUM VARIETY EXHIBITING A HYPER-ACCUMULATION OF ZEAXANTHIN AND PRODUCTS DERIVED THEREFROM - The present invention is concerned with | 2014-03-27 |
20140086987 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans - Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided. | 2014-03-27 |
20140086988 | Stabilized Protein Crystals, Formulations Containing Them and Methods of Making Them - This invention relates to methods for the stabilization, storage and delivery of biologically active macromolecules, such as proteins, peptides and nucleic acids. In particular, this invention relates to protein crystals, formulations and compositions comprising them. Provided are methods and compositions for encapsulating proteins, glycoproteins, enzymes, antibodies, hormones and peptide crystals or crystal formulations into compositions for biological delivery. | 2014-03-27 |
20140086989 | Protein Matrix Vaccine Compositions Including Polycations - The present invention relates to immunogenic compositions containing one or more antigens of interest, one or more carrier proteins, and one or more polycations, wherein the antigen of interest is entrapped with cross-linked carrier protein matrix and one or more polycations, methods of making such vaccines, and methods of vaccine administration. | 2014-03-27 |
20140086990 | SUSTAINED RELEASE SMALL MOLECULE DRUG FORMULATION - An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having C | 2014-03-27 |
20140086991 | Controlled Agglomeration - A process for the preparation of a particu 1265 late material by a controlled agglomeration method, i.e. a method that enables a controlled growth in particle size. The method is especially suitable for use in the preparation of pharmaceutical compositions containing a therapeutically and/or prophylactically active substance which has a relatively low aqueous solubility and/or which is subject to chemical decomposition. The process comprising i) spraying a first composition comprising a carrier, which has a melting point of about 5 DEG C. or more which is present in the first composition in liquid form, on a second composition comprising a material in solid form, the second composition having a temperature of at the most a temperature corresponding to the melting point of the carrier and/or the carrier composition and ii) mixing or others means of mechanical working the second composition onto which the first composition is sprayed to obtain the particulate material. | 2014-03-27 |
20140086992 | Storage-Stable Dust-Free Homogeneous Particulate Formulation - Described is a storage-stable dust-free homogeneous particulate formulation. The formulation consists of (a) at least one water-soluble Vitamin E-derivative, (b) at least one hydrophilic polymer, (c) optionally additional surface-active substances, and (d) optionally additional pharmaceutical additives. The sum of (a), (b), (c) and (d) equals 100% by weight of the formulation. The fines fraction with particle diameters of less than 100 μm is less than 10% by weight. Describe also is a process for manufacturing the formulation, and use of the formulation as a solubilizing composition in pharmaceutical formulations. | 2014-03-27 |
20140086993 | Storage-Stable Dust-Free Homogeneous Particulate Formulation Comprising At Least One Water-Soluble Vitamin E-Derivative And At Least One Hydrophilic Polymer - A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble Vitamin E-derivative and at least one hydrophilic polymer. In one embodiment the storage-stable dust-free homogeneous particle formulation, consists of
| 2014-03-27 |
20140086994 | Synthesis of Small Particles - The invention provides an apparatus for forming fine particles of a substance in a precipitation chamber, in which the apparatus has means to convey the fine particles from the precipitation chamber to at least one particle collection chamber, downstream of the precipitation chamber, the particle collection chamber having an inlet and an outlet separate from the inlet. The invention also provides a method of forming fine particles of a substance, the method comprising contacting a non-gaseous fluid containing the substance with a dense fluid to expand the non-gaseous fluid in a precipitation chamber, conveying a resulting mixture of fluid and the fine particles from the precipitation chamber to a collection chamber, the collection chamber having an inlet and an outlet separate from the inlet. | 2014-03-27 |
20140086995 | POLYMER MICROSPHERE COMPOSITIONS FOR LOCALIZED DELIVERY OF THERAPEUTIC AGENTS - Compositions and methods for localized delivery of a therapeutic agent to a biological tissue over time. The composition includes a temperature-responsive polymer and one or more microspheres, each having degradation rate different from the other, and each comprising a therapeutic agent. In the method, the composition is applied to a biological tissue and forms a gel that adheres to the tissue. | 2014-03-27 |
20140086996 | WATER-SOLUBLE DRUG CARRIER AND PROCESS FOR PRODUCING THE SAME - An object of the present invention is to provide a drug delivery carrier that is free from the drug leakage problem and has an easily controllable particle size, and that can be used to deliver water-soluble drugs such as genes and proteins in a wide range of applications, including delivery of water-soluble drugs that do not have high anionic properties, and also can be used as a non-viral gene vector. The invention also provides a process for production of such drug delivery carriers. The drug delivery carrier of the present invention includes a water-soluble drug double-coated with two types of inner and outer surfactants 1 and 2. | 2014-03-27 |
20140086997 | COATING COMPOSITION SUITABLE FOR PHARMACEUTICAL OR NUTRACEUTICAL DOSAGE FORMS - The invention relates to a coating composition suitable for the coating of a pharmaceutical or nutraceutical dosage form, comprising a core comprising one or more pharmaceutical or nutraceutical active ingredients, wherein the coating composition is comprising at least 20% by weight of an enteric core/shell polymer composition derived from an emulsion polymerisation process, wherein either the core of the core/shell polymer composition is formed by a water-insoluble, not cross-linked polymer or copolymer and the shell of the core/shell polymer composition is formed by an anionic polymer or copolymer or vice versa. | 2014-03-27 |
20140086998 | Compositions And Methods Relating To Solenopsins And Their Uses In Treating Neurological Disorders And Enhancing Physical Performance - Provided herein are piperidine alkaloids and uses thereof in neurological disorders and physical enhancement applications. | 2014-03-27 |
20140086999 | BIOLOGICALLY ACTIVE DIETARY SUPPLEMENT FOR NORMALIZING THE ANDROGEN LEVEL IN MEN AND THE OVERALL CONDITION AND REDUCING OBESITY - Biologically active dietary supplements (BADS) are proposed for normalizing the hormone balance and the overall condition in men based on natural ingredients. The BADS contain white cinquefoil roots and rhizomes or the above-ground part of white cinquefoil, or a mixture thereof, as well as drone brood in a quantity of from 20 mass % to 80 mass %. The disclosure makes it possible to produce a product which demonstrates, by virtue of an optimally selected ratio of ingredients, a synergistic effect in relation to the normalization of the androgen level and the prophylaxis of obesity in men. | 2014-03-27 |
20140087000 | Method and System for Treatment of Biological Tissue - A composition for reconstruction, replacement or repair of damaged or diseased biological tissue comprising an extracellular matrix (ECM) composition that includes an ECM scaffold component derived from a mammalian source and at least one additional bioactive component selected from the group consisting of a statin and a chitin derivative. | 2014-03-27 |
20140087001 | Pharmaceutical Compositions and Topical Use Thereof - The present invention relates to methods for the preparation of compositions comprising adipose tissue-derived secretions, for example those derived from bovine adipose tissue, and the use of such compositions in the preparation of a pharmaceutical composition for topical use. The invention also relates to the use of adipose tissue-derived secretions and pharmaceutical compositions thereof for the topical treatment of a non-inflammatory condition, for example the treatment of a skin condition, and for the stimulation of hair growth in a subject by topical application. The invention also relates to the use of adipose tissue-derived secretions and pharmaceutical compositions thereof for the topical treatment of acne. | 2014-03-27 |
20140087002 | Autologous Lymph Node Transfer In Combination With VEGF-C Or VEGF-D Growth Factor Therapy to Treat Lymphedema And To Improve Reconstructive Surgery - Materials and methods are provided to improve survival of lymph nodes and integration of lymph nodes into a lymphatic network, following lymph node transplantation. The treatment or prevention of lymphedema is also addressed. A method of lymph node transfer includes transferring or transplanting a lymph node or lymph node fragment in a mammalian subject; and administering a composition comprising an agent selected from the group consisting of Vascular Endothelial Growth Factor C (VEGF-C) polynucleotides, VEGF-C polypeptides, Vascular Endothelial Growth Factor D (VEGF-D) polynucleotides, and VEGF-D polypeptides to a perinodal site within 20 cm of the lymph node or lymph node fragment. In certain embodiments, the agent is present in the composition in an amount effective to promote survival of the lymph node and integration of the lymph node into a lymphatic network in the mammalian subject, at the site of transfer or transplantation. | 2014-03-27 |
20140087003 | METHOD FOR TREATING VENOMOUS BITES AND STINGS - A method using an alkaline sodium silicate composition to inhibit the toxic effects of venom and treat venomous bites and stings. | 2014-03-27 |
20140087004 | Gallium-doped phosphocalcic compounds - The present invention relates to a gallium-doped phosphocalcic compound of formula (I): | 2014-03-27 |
20140087005 | MODULATORS OF HSP70/DNAK FUNCTION AND METHODS OF USE THEREOF - Compositions and methods for modulating HSP70 function, particularly for the targeted killing of cancer cells, are disclosed. | 2014-03-27 |
20140087006 | USE OF TRANSPLATIN TO PREVENT HEARING LOSS - Methods and compositions for treating and preventing toxic side effects of platinum-based chemotherapy agents are disclosed, in which transplatin is administered to a subject. Transplatin is shown to have protective effects against cisplatin-induced ototoxicity, nephotoxicity and neurotoxicity. Anti-inflammatory activity of transplatin is demonstrated and methods and compositions for treating and preventing inflammatory pain are described. | 2014-03-27 |
20140087007 | BOWEL CLEANSING PREPARATIONS - Disclosed is a method for rapidly cleansing the intestines and colon of a patient by orally administering an aqueous hypertonic sulfate solution, and then an aqueous isotonic solution to induce purgation, the purgations induced resulting in intestinal and colonic cleansing in less than four hours from the administration of the sulfate solution. | 2014-03-27 |